Logo image of ADIL

ADIAL PHARMACEUTICALS INC (ADIL) Stock Fundamental Analysis

NASDAQ:ADIL - Nasdaq - US00688A2050 - Common Stock - Currency: USD

0.67  -0.11 (-14.1%)

After market: 0.6783 +0.01 (+1.24%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADIL. ADIL was compared to 198 industry peers in the Pharmaceuticals industry. ADIL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ADIL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ADIL had negative earnings in the past year.
ADIL had a negative operating cash flow in the past year.
In the past 5 years ADIL always reported negative net income.
ADIL had a negative operating cash flow in each of the past 5 years.
ADIL Yearly Net Income VS EBIT VS OCF VS FCFADIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

ADIL has a worse Return On Assets (-261.65%) than 90.91% of its industry peers.
ADIL has a Return On Equity of -324.41%. This is in the lower half of the industry: ADIL underperforms 73.74% of its industry peers.
Industry RankSector Rank
ROA -261.65%
ROE -324.41%
ROIC N/A
ROA(3y)-197.33%
ROA(5y)-210.06%
ROE(3y)-279.33%
ROE(5y)-332.84%
ROIC(3y)N/A
ROIC(5y)N/A
ADIL Yearly ROA, ROE, ROICADIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADIL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADIL Yearly Profit, Operating, Gross MarginsADIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ADIL has more shares outstanding
Compared to 5 years ago, ADIL has more shares outstanding
There is no outstanding debt for ADIL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ADIL Yearly Shares OutstandingADIL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADIL Yearly Total Debt VS Total AssetsADIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

ADIL has an Altman-Z score of -24.29. This is a bad value and indicates that ADIL is not financially healthy and even has some risk of bankruptcy.
ADIL has a worse Altman-Z score (-24.29) than 87.37% of its industry peers.
ADIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -24.29
ROIC/WACCN/A
WACCN/A
ADIL Yearly LT Debt VS Equity VS FCFADIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 4.16 indicates that ADIL has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.16, ADIL is doing good in the industry, outperforming 64.65% of the companies in the same industry.
ADIL has a Quick Ratio of 4.16. This indicates that ADIL is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.16, ADIL is doing good in the industry, outperforming 66.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.16
Quick Ratio 4.16
ADIL Yearly Current Assets VS Current LiabilitesADIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

ADIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.09%, which is quite impressive.
EPS 1Y (TTM)55.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ADIL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.34% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.16%
EPS Next 2Y17.34%
EPS Next 3Y14.82%
EPS Next 5Y18.34%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADIL Yearly Revenue VS EstimatesADIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M 200M
ADIL Yearly EPS VS EstimatesADIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADIL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADIL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADIL Price Earnings VS Forward Price EarningsADIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADIL Per share dataADIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

ADIL's earnings are expected to grow with 14.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.34%
EPS Next 3Y14.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADIL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADIAL PHARMACEUTICALS INC

NASDAQ:ADIL (5/2/2025, 8:00:00 PM)

After market: 0.6783 +0.01 (+1.24%)

0.67

-0.11 (-14.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-04 2025-03-04/bmo
Earnings (Next)05-12 2025-05-12/amc
Inst Owners9.87%
Inst Owner Change-9.21%
Ins Owners1.33%
Ins Owner Change0%
Market Cap4.40M
Analysts80
Price Target6.63 (889.55%)
Short Float %3.35%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.52%
Min EPS beat(2)9.7%
Max EPS beat(2)15.33%
EPS beat(4)2
Avg EPS beat(4)-16.82%
Min EPS beat(4)-84.19%
Max EPS beat(4)15.33%
EPS beat(8)4
Avg EPS beat(8)5.29%
EPS beat(12)7
Avg EPS beat(12)10.16%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.33%
PT rev (3m)-13.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-31.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-1.94
EYN/A
EPS(NY)-1.78
Fwd EYN/A
FCF(TTM)-1.05
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0
BVpS0.62
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -261.65%
ROE -324.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-197.33%
ROA(5y)-210.06%
ROE(3y)-279.33%
ROE(5y)-332.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.16
Quick Ratio 4.16
Altman-Z -24.29
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.07%
EPS Next Y8.16%
EPS Next 2Y17.34%
EPS Next 3Y14.82%
EPS Next 5Y18.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.7%
OCF growth 3YN/A
OCF growth 5YN/A